Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2004 | 1 |
2005 | 1 |
2006 | 1 |
2007 | 1 |
2008 | 1 |
2010 | 1 |
2019 | 1 |
2024 | 0 |
Search Results
6 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
Modified vaccinia Ankara: potential as an alternative smallpox vaccine.
Clin Infect Dis. 2004 Jun 15;38(12):1749-53. doi: 10.1086/421266. Epub 2004 May 19.
Clin Infect Dis. 2004.
PMID: 15227622
Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax challenge in vaccinia-naïve and vaccinia-immune individuals.
Parrino J, McCurdy LH, Larkin BD, Gordon IJ, Rucker SE, Enama ME, Koup RA, Roederer M, Bailer RT, Moodie Z, Gu L, Yan L, Graham BS; VRC 201/203 Study Team.
Parrino J, et al. Among authors: larkin bd.
Vaccine. 2007 Feb 9;25(8):1513-25. doi: 10.1016/j.vaccine.2006.10.047. Epub 2006 Nov 7.
Vaccine. 2007.
PMID: 17126963
Free PMC article.
Clinical Trial.
Item in Clipboard
A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial.
Martin JE, Louder MK, Holman LA, Gordon IJ, Enama ME, Larkin BD, Andrews CA, Vogel L, Koup RA, Roederer M, Bailer RT, Gomez PL, Nason M, Mascola JR, Nabel GJ, Graham BS; VRC 301 Study Team.
Martin JE, et al. Among authors: larkin bd.
Vaccine. 2008 Nov 25;26(50):6338-43. doi: 10.1016/j.vaccine.2008.09.026. Epub 2008 Sep 26.
Vaccine. 2008.
PMID: 18824060
Free PMC article.
Clinical Trial.
Item in Clipboard
Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses.
Koup RA, Roederer M, Lamoreaux L, Fischer J, Novik L, Nason MC, Larkin BD, Enama ME, Ledgerwood JE, Bailer RT, Mascola JR, Nabel GJ, Graham BS; VRC 009 Study Team; VRC 010 Study Team.
Koup RA, et al. Among authors: larkin bd.
PLoS One. 2010 Feb 2;5(2):e9015. doi: 10.1371/journal.pone.0009015.
PLoS One. 2010.
PMID: 20126394
Free PMC article.
Clinical Trial.
Item in Clipboard
An HIV vaccine: as we build it, will they come?
McCluskey MM, Alexander SB, Larkin BD, Murguia M, Wakefield S.
McCluskey MM, et al. Among authors: larkin bd.
Health Aff (Millwood). 2005 May-Jun;24(3):643-51. doi: 10.1377/hlthaff.24.3.643.
Health Aff (Millwood). 2005.
PMID: 15886155
Item in Clipboard
Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study.
Gaudinski MR, Coates EE, Novik L, Widge A, Houser KV, Burch E, Holman LA, Gordon IJ, Chen GL, Carter C, Nason M, Sitar S, Yamshchikov G, Berkowitz N, Andrews C, Vazquez S, Laurencot C, Misasi J, Arnold F, Carlton K, Lawlor H, Gall J, Bailer RT, McDermott A, Capparelli E, Koup RA, Mascola JR, Graham BS, Sullivan NJ, Ledgerwood JE; VRC 608 Study team.
Gaudinski MR, et al.
Lancet. 2019 Mar 2;393(10174):889-898. doi: 10.1016/S0140-6736(19)30036-4. Epub 2019 Jan 24.
Lancet. 2019.
PMID: 30686586
Free PMC article.
Clinical Trial.
Item in Clipboard
Cite
Cite